Use of oral osmotic hydromorphone in opioid switch for cancer pain
Hydromorphone is a semi-synthetic opioid and it is a powerful µ receptor agonist. Hydromorphone has a short half-life (approximately 1 hour), but the controlled release formulation Oral Osmotic extends the duration of action and provides constant pain control. The aim of this study was to assess eff...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publiediting
2008-09-01
|
| Series: | Pathos |
| Subjects: | |
| Online Access: | http://www.pathos-journal.com/doc/2008_3_Rassegna_Palomba.pdf |